Navigation Links
Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
Date:4/14/2008

-- Lead NNRTI RDEA806 to begin Phase 2b trial in the second quarter of 2008

--

MONTREAL and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data was presented on the Company's next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds demonstrating potent activity against the human-immunodeficiency virus (HIV), including NNRTI- resistant strains, with the potential for improved performance over current NNRTIs.

The data were presented at the 21st International Conference on Antiviral Research (ICAR) in Montreal, Quebec, Canada.

The compounds in this series are potent against both wild-type and the most common NNRTI-resistant viruses and are more active than efavirenz (Sustiva(R), BMS) and nevirapine (Viramune(R), Boehringer-Ingelheim) against a broad panel of NNRTI-resistant clinical isolates.

"Safer, better tolerated NNRTIs that also work against viruses resistant to the most widely used NNRTIs, are needed to expand the armamentarium," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Our lead NNRTI, RDEA806, has shown the potential to match this profile and we are preparing to progress it into a Phase 2b trial later this quarter. An important part of our business strategy is to progress an additional next generation NNRTI, from the structurally novel series presented today, into Phase 1 later this year."

The poster is available on the Company website (http://www.ardeabio.com) under the title, "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses."

About RDEA806 '/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... lesions are cancerous is described by University of Illinois researchers in the ... and photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ...
(Date:8/25/2015)... PETERSBURG, Fla. , Aug. 25, 2015 /PRNewswire/ ... announced today that it has been awarded Certification ... Quality Assurance (NCQA). NCQA is ... quality. NCQA accredits and certifies a wide range of ... in key areas of performance. "Our ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4InformedDNA Achieves NCQA Utilization Management Certification 2
... Polytechnic Institute have developed a new method to harvest ... the creation of self-powered microsensors for more accurate and ... Koratkar, the researchers investigated how the flow of water ... small amounts of electricity. The research team demonstrated the ...
... , , • NT-KO-003, developed by ... neuroprotective effects that does not cause,immunosuppression. ... administered orally, whereas the few treatments available in,Spain require ... • NeuroAdvan, the Phase IIa clinical ...
... 2011 , Convergence Pharmaceuticals Limited ("Convergence"), ... value analgesic,medicines, today announces that the Phase II proof ... lumbosacral,radiculopathy (LSR) has started. LSR is a ... roots in the lumbar region of the spine. Common,features ...
Cached Biology Technology:New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 2Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 3Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 4
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... team of scientists, led by Monash University researchers, has ... hospital patients worldwide - a discovery that has the ... of dollars each year. The research published today ... ways to genetically modify the bacterium Clostridium difficile ...
... with the 200th anniversary of the birth of Charles ... Behavioural Processes "Comparative Cognition in Context" was ... Hollis, the special issue features 16 papers original ... by leading researchers in the field of comparative cognition, ...
... issue of BioScience includes the following peer-reviewed articles: ... Science. , Patrick J. Tranel and David P. Horvath. ... including the development of herbicide-resistant crops and a better ... next generation of tools, including genomics, could yield novel ...
Cached Biology News:Monash scientists debug superbug 2BioScience tip sheet, March 2009 2
... Zero -mr agarose is ... no detectable endoosmosis, and is ... high molecular weight proteins or ... varying degrees of molecular sieving ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... By incorporating a wide range of ... NX sets a new standard for flexible ... liquid handling including pipetting, dilution, dispensing, ... system thats as powerful and flexible as ...
Biology Products: